Abstract
Sepsis is the most common cause of acute kidney injury (AKI) in the intensive care unit. Mortality of AKI is much higher in septic patients compared with nonseptic patients. Septic patients frequently present with a hyperdynamic circulation including primary arterial vasodilation and a secondary increase in cardiac output; renal hemodynamics are often characterized by early vasoconstriction. The elucidation of key components of pathogenesis of sepsis and septic shock has suggested several potential therapies for sepsis, and significant progress has been made in understanding the biology and mechanisms of endotoxin-related AKI; however, translation of this knowledge into improved management and outcome for patients with AKI has not been optimal. This chapter summarizes the hemodynamic and biochemical alterations in sepsis which lead to AKI and addresses the currently available and potential future therapies for the management of sepsis to prevent and treat AKI.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdelrahman M, Sharples E, McDonald M, et al. (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22(1): pp. 63–9.
Abraham E, Lattere F, Garg E, et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353(13): pp. 1332–41.
Angus DC, Linde-Zwirble WT, Lidicker J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7): pp. 1303–10.
Annane D, Sebille V, Charpentier C, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7): pp. 862–71.
Benedict CR, Rose JA (1992) Arterial norepinephrine changes in patients with septic shock. Circ Shock 38(3): pp. 165–72.
Bernard GR, Vincent JL, Laterre PF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10): pp. 699–709.
Brivet FG, Kleinknecht DJ, Loirat P, et al. (1996) Acute kidney failure in intensive care units – causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 24(2): pp. 192–8.
Brunkhorst F, Engel C, Bloss F, et al. (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358(2): pp. 125–139.
Court O, Kumar A, Parrillo JE (2002) Clinical review: MyoÂcardial depression in sepsis and septic shock. Crit Care 6(6): pp. 500–8.
Cumming A, Driedger A, McDonald J, et al. (1988) Vasoactive hormones in the renal response to systemic sepsis. Am J Kidney Dis 11(1): pp. 23–32.
Dellinger R (2007) Update on clinical trials in severe sepsis. LIPOS antiendotoxin trial. in Society of Critical Care Medicine 36th Critical Care Congress, Orlando, FL.
Dong X, Swaminathan S, Bachman LA, et al. (2007) Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 71(7): pp. 619–28.
Dubois M-J, Orellan-Jimeniz C, Melot C, et al. (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med 34(10); pp. 2536–2540.
Finfer S, Bellomo F, Boyce N, et al. (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350(22): pp. 2247–56.
Finney SJ, Zekveld C, Elia A, et al. (2003) Glucose control and mortality in critically ill patients. JAMA 290(15): pp. 2041–7.
Gattinoni L, Brazzi L, Pelosi P, et al. (1995) A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 333(16): pp. 1025–32.
Grover R, Zaccarddelli D, Colice G, et al. (1999) An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 27(5): pp. 913–22.
Hayes MA, Timmins AC, Yau EHS, et al. (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330(24): pp. 1717–22.
Knotek M, Esson M, Gengaro P, et al. (2000) Desensitization of soluble guanylate cyclase in renal cortex during endotoxemia in mice. J Am Soc Nephrol 11(11): pp. 2133–7.
Kon V, Badr KF. (1991) Biological actions and pathophysiologic significance of endothelin in the kidney. Kidney Int 40(1): pp. 1–12.
Lacherade J, Jabre P, Bastuji-Garin S, et al. (2007) Failure to achieve glycemic control despite intensive insulin therapy in a medical ICU: incidence and influence on ICU mortality. Intensive Care Med 33(5): pp. 814–21.
Landry DW, Oliver JA (2001) The pathogenesis of vasodilatory shock. N Engl J Med 345(8): pp. 588–95.
Lin SM, Huang CD, Lin HC, et al. (2006) A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: A randomized controlled trial. Shock 26: pp. 551–557.
Mitra A, Bansal S, Wang W, et al. (2007) Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 22(8): pp. 2349–53.
Neveu H, Kleinknecht D, Brivet F, et al. (1996) Prognostic factors in acute kidney failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 11(2): pp. 293–9.
Ortega R, Gines P, Uriz J, et al. (2002) Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36(4 Pt 1): pp. 941–8.
Otero R, Nguyen B, Huang D, et al. (2006) Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest 130(5): pp. 1579–95.
Patel N, Sharples E, Cuzzocrea S, et al. (2004) Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66(3): pp. 983–9.
Rangel-Frausto MS, Pittet D, Costigan M, et al. (1995) The natural history of the systemic inflammatory response Âsyndrome (SIRS). A prospective study. JAMA 273(2): pp. 117–23.
Richard C, Warszawski J, Anguel N, et al. (2003) Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 290(20): pp. 2713–20.
Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invst 112(4): pp. 460–7.
Rivers E, Nguyen B, Havstad S, et al. (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19): pp. 1368–77.
Russell JA (2007) Hemodynamic support of sepsis. Vasopressin versus norepinephrine for septic shock. in Society of Critical Care Medicine 36th Critical Care Congress Orlando, Florida.
Russell JA (2007) Vasopressin in septic shock. Crit Care Med 35(9 Suppl): pp. S609–15.
Sanz E, Lopez N, Linares M, et al. (1990) Intravascular and interstitial fluid dynamics in rats treated with minoxidil. J Cardiovasc Pharmacol 15(3): pp. 485–92.
Schrier RW, Abraham E (1995) Aggressive volume Âexpansion and pseudo-ARDS. Hosp Pract (Minneap) 30(6): pp.19, 23.
Schrier RW, Wang W (2004) Acute kidney failure and sepsis. N Engl J Med 351(2): pp. 159–69.
Schwartz D, Mendonca M, Schwartz I, et al. (1997) Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 100(2): pp. 439–48.
Sort P, Navasa M, Arroya V, et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341(6): pp. 403–9.
Sprung C, Annane D, Keh D, et al. (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2): pp. 111–24.
Thiemermann C, Szalbo C, Mitchell J, et al. (1993) Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA 90(1): pp. 267–71.
Wang W, Falk S, Jittikanont S, et al. (2002) Protective effect of renal denervation on normotensive endotoxemia-induced acute kidney failure in mice. Am J Physiol Renal Physiol 283(3): pp. F583–7.
Wang W, Jittikanont S, Falk S, et al. (2003) Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol, 284(3): pp. F532–7.
Wang W, Poole B, Mitra A, et al. (2004) Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxin-induced acute renal failure. Am J Physiol Renal Physiol. 287(5): pp. F1044–8.
Wang W, Zolty E, Falk S, et al. (2006) Pentoxifylline protects against endotoxin-induced acute kidney failure in mice. Am J Physiol Renal Physiol 291(5): pp. F1090–5.
Wang W, Zolty E, Falk S, et al. (2007) Prostacyclin in endotoxemia-induced acute kidney injury: cyclooxygenase inhibition and renal prostacyclin synthase transgenic mice. Am J Physiol Renal Physiol 293(4): pp. F1131–6.
Van den Berghe G, Wilmer A, Hermans G, et al. (2006) Intensive insulin therapy in the medical ICU. N Engl J Med 354(5): pp. 449–61.
Van den Berghe G, Wouters P, Weekers F, et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19): pp. 1359–67.
Vanhorebeek I, De Vos R, Mesotten D, et al. (2005) Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 365(9453): pp. 53–9.
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network (2000) N Engl J Med 342(18): pp. 1301–8.
Wheeler A, Bernard G, Thompson B, et al. (2006) Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354(21): pp. 2213–24.
Wiedemann H, Wheeler A, Bernard G, et al. (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354(24): pp. 2564–75.
Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187(3–5): pp. 447–63.
Acknowledgments
The authors’ research papers cited in the article were supported by NIH Grant 2 RO1 DK052599–09A2. The authors appreciate the editorial assistance of Jan Darling.
Acute kidney injury (AKI) is frequently associated with sepsis. In severe sepsis and septic shock, the incidence of AKI has been reported to be 23% and 51%, respectively [31]. Sepsis is the most common cause of AKI in intensive care units, accounting for approximately 50% of cases [29]. The mortality of AKI is reported to be much higher in septic, as compared with nonseptic, patients (73 vs 45%) [7]. The incidence of sepsis is increasing, in part due to the aging of the population worldwide. In the United States the annual mortality secondary to sepsis is an estimated 210,000, a number which equals or exceeds that due to heart attacks [3].
The management of the patient with sepsis and AKI necessitates an understanding of the multifactorial pathogenesis as discussed in this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schrier, R.W., Bansal, S., Wang, W. (2010). Acute Kidney Injury in Sepsis. In: Jörres, A., Ronco, C., Kellum, J. (eds) Management of Acute Kidney Problems. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69441-0_28
Download citation
DOI: https://doi.org/10.1007/978-3-540-69441-0_28
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69413-7
Online ISBN: 978-3-540-69441-0
eBook Packages: MedicineMedicine (R0)